Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=510 Promoting Altruism to Enhance Vaccine Acceptance
Vaccine Refusal
Primary: Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. — -0.4 units on a scale
Phase 3 N=1,054 A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)
Papillomavirus Infections
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 1637.9; 1725.0; 1170.3; 1212.6 milli Merck…
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
N/A N=60 VISTA: Vaccinator-Initiated Screening and TAilored Counseling for Reducing Vaccine Hesitancy
Vaccination Uptake
Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women
N/A N=7,879 Education Bundle to Decrease Patient Refusal of VTE Prophylaxis
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolism
Primary: Percentage of Non Administration of Prescribed VTE Prophylaxis Medication Doses — 9.1; 13.6; 5.6; 13.3 Percentage of nonadministration — p=<0.05
Phase 2 N=71 Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Relapsing Forms of Multiple Sclerosis
Primary: Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level — 73; 68 percentage of participants — p=0.692
Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
Phase 1 N=315 Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Pertussis
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1. — 28; 31; 48; 18 IU/mL
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
N/A N=31 Safe Administration of Flu Vaccine to Egg Allergic Children
Egg Allergy
Primary: Categorical Reactivity to Vaccine as it Was Administered — 17; 14; 3; 4 Participants
Phase 4 N=3,032 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
N/A N=3,493 Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Phase 3 N=1,412 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
N/A N=338,718 Developing and Testing a COVID-19 Vaccination Acceptance Intervention
COVID-19 Vaccination
Primary: Receipt of Any Dose COVID-19 Vaccination — 57621; 65407 Participants — p=0.202
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
N/A N=756 Views on COVID-19 and Vaccination
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
N/A N=164,205 Patient Portal - Flu Reminder Recall
Influenza · Respiratory Tract Infections · Vaccines
Primary: 1.Receipt of the Annual Influenza Vaccine (Between 10/1/18 - 4/2/19) Among Index Patients. Outcomes Will be Assessed Via Vaccine Data Extraction From the Electronic…
Phase 3 N=207 A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
Hepatitis B
Primary: Percentage of Participants With a Protective Hepatitis B Surface Antibody Level of ≥10 Milli International Units/mL (mIU/mL) at 30 Days Post-Challenge With HBVAXPRO™…
N/A N=228,831 Precision Vaccine Promotion in Underserved Populations
Influenza · Vaccine Hesitancy
Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216
Phase 4 N=480 Immunogenicity of Hepatitis B Vaccination Among Drug Users
Hepatitis B Vaccination
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 142; 138; 0 Participants
Phase 3 N=1,315 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Bacterial Infections · Virus Diseases
Primary: Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)…
Phase 3 N=754 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
Hepatitis B · Pertussis
Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants
N/A N=3,331 Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
N/A N=200 Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
Human Papillomavirus Infection
Primary: Geometric Mean Antibody Titers Following the Third Dose of Human Papilloma Virus (HPV) Vaccine by Virus Type and by Administration Schedule — 1894; 4221; 1773; 5623…
Phase 2 N=52 Combination Vaccination Before HIV Treatment Interruption
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
Phase 4 N=120 Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres